Clinica Baviera SA

As of June 30, 2026, Clinica Baviera SA carries a market capitalization of 923.14M, placing it among publicly traded companies globally. Its enterprise value stands at 882.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Clinica Baviera SA's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Clinica Baviera SA has 16.03M shares outstanding.

As of June 30, 2026, Clinica Baviera SA trades at a trailing price-to-earnings ratio of 20.09. The price-to-sales ratio is 2.91, and the price-to-book ratio stands at 8.27.

As of June 30, 2026, Clinica Baviera SA trades at an EV/EBITDA multiple of 9.74 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.66 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Clinica Baviera SA trades at an EV/FCF ratio of 19.04, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 882.09M versus a market cap of 923.14M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Clinica Baviera SA maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Clinica Baviera SA posted a return on equity (ROE) of 45.47, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 39.07 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 19.26, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 41.29, useful for judging operating efficiency across full business cycles. The company generates approximately 169,303.90 in revenue per employee across its workforce of 1,872.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Clinica Baviera SA recorded 17.98M in income tax expense. That works out to an effective tax rate of 27.75, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 64.78M, leaving 45.95M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Clinica Baviera SA's stock has gained approximately 27.79% over the past 52 weeks. The 50-day moving average sits at 57.03, while the 200-day moving average is 55.00.

Over the twelve months ended June 30, 2026, Clinica Baviera SA generated 316.98M in revenue and converted that into 45.95M in net income, yielding earnings per share of 2.92. EBITDA reached 90.54M, while operating income came in at 64.58M.

As of June 30, 2026, Clinica Baviera SA holds 51.59M in cash and equivalents against 9.90M in total debt, resulting in a net debt position of -2.87M. Total book value stands at 111.57M, with working capital of -4.03M providing operational flexibility.

Clinica Baviera SA produced 77.15M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -30.83M in capital expenditures, free cash flow totaled 46.32M - equivalent to 2.89 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of 20.37 and net profit margin of 14.50 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Clinica Baviera SA paid dividends of 0.03 per share. The dividend payout ratio of 0.89 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.02, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.04, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Clinica Baviera SA shareholders.

As of June 30, 2026, Clinica Baviera SA has an Altman Z-Score of 6.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.